Corcept Therapeutics Incorporated (CORT)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	106,140	91,386	94,616	94,500	101,418	116,870	112,733	111,844	112,512	106,453	97,607	99,411	106,011	109,398	114,113	105,972	94,181	86,808	78,215	76,225
Total stockholders’ equity	US$ in thousands	506,705	461,679	421,614	529,584	501,842	473,364	442,326	407,811	375,806	540,229	522,675	510,802	523,338	489,680	453,698	409,489	371,182	334,376	298,053	285,755
ROE		20.95%	19.79%	22.44%	17.84%	20.21%	24.69%	25.49%	27.43%	29.94%	19.71%	18.67%	19.46%	20.26%	22.34%	25.15%	25.88%	25.37%	25.96%	26.24%	26.67%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $106,140K ÷ $506,705K
= 20.95%

To analyze Corcept Therapeutics Inc's return on equity (ROE) based on the provided data, we can observe fluctuations in ROE over the past eight quarters.

The ROE has shown some variability, ranging from a low of 17.84% in Q1 2023 to a high of 27.43% in Q2 2022. In general, ROE has remained relatively healthy, with the majority of values above 20%, indicating that the company is efficiently generating profits from its shareholders' equity.

However, there was a slight downward trend in ROE from Q2 2022 to Q1 2023 before showing a modest increase in Q2 2023. This trend suggests that the company may have faced challenges in maintaining or improving its profitability during the indicated periods.

Overall, while Corcept Therapeutics Inc's ROE performance has been satisfactory, stakeholders may benefit from further analysis to determine the factors influencing the fluctuations in ROE and potential strategies to enhance shareholder value in the future.